Tivic Health Systems, Inc.

Tivic Health Systems, Inc. is a commercial-phase health technology company developing and commercializing bioelectronic medicine to improve health, treat certain conditions and diseases, and make a meaningful difference in people’s lives.

Tivic believes consumers want more drug-free solutions, and is focusing on providing more non-invasive, drug free options directly to consumers. Tivic utilizes its patented technology and is in the process of building a pipeline of products across various treatment areas, beginning with sinus pain and congestion, with the goal of expanding its products and indications of use to address post-operative pain and migraine. Developing non-invasive products generally leads to shorter development timelines, lower risk, and broader applicability.

Nasdaq: TIVC
IR Website: https://tivichealth.com/investor/
Headquarters: Hayward, CA

Tivic’s first FDA approved, CE marked commercial product, ClearUP® Sinus Pain Relief (“ClearUP”), provides consumers with a new solution to treat sinus pain and congestion from nasal allergies, sinus infections, chronic sinusitis, colds, and flu. According to Mintel Group Ltd., as of 2019, treatments for these indications amounted to an approximately $9.9B market in the U.S., which market is currently dominated by pharmaceutical products.

Bioelectronic Medicine and Market

Tivic Technology and Pipeline

ClearUP: A Unique Solution for an Age-Old Problem

Investor Presentation

Press Releases

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

SEC Filings

Management Overview

Risks & Disclosures


The Tivic Health management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Tivic Health story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.